Pfizer CEO Albert Bourla joins CNBC's 'Special Report' as President-elect Donald Trump is inaugurated as the 47th U.S. president, becoming the second to serve two non-consecutive terms.
What would it take to make over $3,000 this year with only barely lifting a finger? My answer is having $50,000 and spending five minutes or so using an online brokerage.
In the world of speculative investments like meme coins, the "Greater Fool Theory" thrives. While some see huge profits, I prefer the stability of dividend stocks for steady growth. While others chase
A little money can go a long way. That's especially the case when you invest in stocks that pay you to own them.
There is an often overlooked difference between income investing and dividend growth investing. The two are not the same. Timely charts showing that inflation is even more subdued than the official CP
Dividend yields can be like ladders: The higher you go, the scarier it gets. Many of us are more afraid of falling off an especially tall ladder than a shorter one.
PITTSBURGH, Jan. 17, 2025 (GLOBE NEWSWIRE) -- A California woman has filed a class-action lawsuit claiming pharmaceutical giants Pfizer (PFE) and Viatris (VTRS), among others, manufactured and sold De

3 Upcoming Dividend Increases

06:21am, Friday, 17'th Jan 2025
This week's anticipated dividend increases feature three companies with an average increase of 8.9% and a median increase of 8.7%. My strategy focuses on buying, holding, and adding companies that con

What To Expect From PFE Stock In 2025?

10:17am, Wednesday, 15'th Jan 2025
Pfizer stock (NYSE: PFE) lost about 5% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli Lilly st
Vaxcyte's stock surged 68% since August 2023, driven by progress with its pneumococcal conjugate vaccine candidates, VAX-24 and VAX-31. VAX-31, covering 95.6% of serotypes, has been selected over VAX-

Why Pfizer sold its $3 billion stake in Haleon

05:33am, Wednesday, 15'th Jan 2025
Pfizer's decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a volatile pharmaceutical market. The transaction, involving 700 million share
Medicine is the cornerstone of healthcare. That remains true today, with a global pharmaceutical industry valued at $1.4 trillion and expected to grow at 6.1% annually through 2030.
Pfizer Inc (NYSE:PFE, ETR:PFE) plans to sell around 700 million shares of Haleon PLC (LSE:HLN, NYSE:HLN), representing a 7.7% stake, via a secondary offering through an accelerated book-building proce
The sale decreases Pfizer's shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from 15%.
Pfizer (PFE) reachead $26.41 at the closing of the latest trading day, reflecting a -1.46% change compared to its last close.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE